We suggest that targeting chromatin-bound activated Chk1, as well as GCN5, PCAF, p300/CBP, c-Jun, and ATF2, might be a novel potential molecular therapy for the prevention of UC-related tumour progression. This evidence concerns the gene ATF2 and neoplasm.